Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Low-intensity pulsed ultrasound as a strategy to boost exosome secretion by adipose-derived stem cells and uptake for myocardial infarction therapy.

Jiang R., Wang H., Zhong F., Hu Y., Liu J., Chen Y.

Animal Study on Cardiovascular Disease, published in Biomed Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Mater (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40578386
DOI
10.1088/1748-605X/ade925
Citations
1

Abstract (original English)

Acute myocardial infarction (MI) remains a major global health issue, with limited therapeutic strategies to repair damaged myocardial tissue and improve long-term cardiac function. Exosome-based therapies, particularly those derived from adipose-derived stem cells (ADSCs), have shown significant promise in promoting cardiac repair. However, the low yield of exosomes from ADSCs has limited their clinical application. In this study, we investigate the potential of low-intensity pulsed ultrasound (LIPUS) to enhance exosome release from ADSCs and promote myocardial recovery. Our results demonstrate that LIPUS at 0.8 W cm -2 for 10 min effectively increases ADSC-derived exosome production by approximately 50% through inhibiting autophagy. Additionally, LIPUS treatment promotes the uptake of exosomes by hypoxic myocardial cells, further enhancing the therapeutic potential of ADSC-exosomes in MI. In vivo , the combination of LIPUS and exosomes significantly improved cardiac function, reduced inflammation, and attenuated myocardial apoptosis and fibrosis in a rat model of MI. These findings suggest that LIPUS can serve as a non-invasive strategy to boost exosome secretion and uptake, offering a promising approach for MI therapy.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ExosomesMyocardial InfarctionAnimalsRatsUltrasonic WavesAdipose TissueStem CellsApoptosisMaleRats, Sprague-Dawley

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research